Veldman J E
Department of Otorhinolaryngology, University Hospital Utrecht, The Netherlands.
Ann N Y Acad Sci. 1997 Dec 29;830:179-86. doi: 10.1111/j.1749-6632.1997.tb51889.x.
Since 1979, when McCabe first described a pattern of bilateral sensorineural hearing loss (SNHL) characterized by a rapid progression over days to weeks, the postulated autoimmune basis of this disease remains unknown. Various attempts have been made to develop the best assays that will clinically confirm the diagnosis and will help identify those patients who may respond to immunosuppressive therapy. The Western blot assay has now been widely applied by different research groups. It has been suggested that antibody to the 68-kD protein is most closely associated with this disorder. Recent analyses suggest that the protein of interest is probably a heatshock protein (hsp 70) with this molecular weight. This disease pattern of rapidly progressive bilateral SNHL presents itself clinically as a different disease than endolymphatic hydrops with fluctuating SNHL, and it is most often associated with vertigo and roaring tinnitus. Meniere's disease may be also immune-mediated, but lacks an autoimmune basis. Its etiopathogenesis is different. A critical review of our own Western blot analyses from patients with either idiopathic rapidly progressive SNHL (N = 33), sudden deafness (N = 53), or other SNHL forms (N = 71) is presented. Immuno-suppressive treatment responses were evaluated. A new concept of immune-mediated endolymphatic hydrops was also further developed on the basis of recent experimental data and earlier clinical observations in order to focus on another aspect of this most intriguing inner-ear disease.
自1979年麦凯布首次描述一种以数天至数周内快速进展为特征的双侧感音神经性听力损失(SNHL)模式以来,该疾病假定的自身免疫基础仍不清楚。人们进行了各种尝试,以开发出最佳检测方法,用于临床确诊并帮助识别那些可能对免疫抑制治疗有反应的患者。蛋白质印迹检测法现已被不同研究小组广泛应用。有人提出,针对68-kD蛋白的抗体与这种疾病关系最为密切。最近的分析表明,感兴趣的蛋白质可能是一种具有该分子量的热休克蛋白(hsp 70)。这种快速进展的双侧SNHL疾病模式在临床上表现为与伴有波动性SNHL的内淋巴积水不同的疾病,并且最常与眩晕和轰鸣性耳鸣相关。梅尼埃病也可能是免疫介导的,但缺乏自身免疫基础。其发病机制不同。本文对我们自己对特发性快速进展性SNHL患者(N = 33)、突发性聋患者(N = 53)或其他SNHL形式患者(N = 71)进行的蛋白质印迹分析进行了批判性综述。评估了免疫抑制治疗反应。基于最近的实验数据和早期的临床观察,还进一步发展了免疫介导性内淋巴积水的新概念,以便关注这种最引人入胜的内耳疾病的另一个方面。